Veru Shares Jump 160% on Free Wegovy Supply for Phase 2b Trial
NVO•Veru's shares surged over 160% after securing a clinical supply agreement with Novo Nordisk for free Wegovy doses in its Phase 2b PLATEAU trial evaluating enobosarm in 200 obese adults. Veru retains commercialization rights to enobosarm and grants Novo Nordisk a right of first negotiation for future GLP-1 combination deals.
1. Clinical Supply Agreement
Veru entered into an agreement with Novo Nordisk under which Novo Nordisk will provide its GLP-1 therapy Wegovy at no cost for the Phase 2b PLATEAU trial. Veru will sponsor and conduct the study, handling trial design, protocol amendments and safety data collection.
2. Market Reaction
Shares of Veru jumped over 160% intraday following the announcement of the clinical supply deal, reflecting investor enthusiasm for a potential combination approach in obesity treatment and validation from a leading market player.
3. Rights and Negotiation Clause
Veru retains full global development and commercialization rights to its selective androgen receptor modulator enobosarm. The company granted Novo Nordisk a right of first negotiation on any future agreement involving enobosarm combined with Novo Nordisk’s GLP-1 therapies.
4. Trial Design and Timeline
The PLATEAU trial will enroll approximately 200 obese adults to assess whether enobosarm preserves muscle mass and physical function when added to Wegovy. Veru expects interim lean mass and fat mass data in Q1 2027 and topline results by Q4 2027.
